Category: MedImpact
-
Rite Aid defeats MedImpact in $200 million Elixir sale dispute By Reuters
•
Written by Dietrich Knuth NEW YORK (Reuters) – MedImpact’s attempt to recover about $200 million in connection with its purchase of Rite Aid’s (NYSE:) pharmacy benefits unit failed after a judge ruled on Monday that it assumed Elixir’s debt when it bought the company. U.S. Bankruptcy Judge Michael Kaplan, at…